USAntibiotics Appoints Eric Wesoloski Vice President of Quality and Regulatory Affairs
USAntibiotics , the sole licensed American manufacturer of penicillin-based Amoxicillin and Amoxil Clavulanate, the life-saving antibiotics commonly known as Amoxil® and Augmentin®, today announced the appointment of Eric Wesoloski to the position of vice president of quality and regulatory affairs.
- USAntibiotics , the sole licensed American manufacturer of penicillin-based Amoxicillin and Amoxil Clavulanate, the life-saving antibiotics commonly known as Amoxil® and Augmentin®, today announced the appointment of Eric Wesoloski to the position of vice president of quality and regulatory affairs.
- In this role, Wesoloski leads all aspects of quality assurance and control, compliance, regulatory affairs and pharmacovigilance related to the manufacturing, packaging, distribution and post-marketing requirements for the company’s antibiotics.
- With more than 30 years in the life sciences industry, Wesoloski’s experience spans markets that include biologics, nutraceuticals, medical devices and pharmaceuticals.
- “We are pleased to welcome Eric Wesoloski to USAntibiotics as vice president of quality and regulatory affairs,” said Patrick Cashman, president, USAntibiotics.